Gene Solutions’ Introduction to Medical Societies in Singapore

At the BPOF & APGCS 2024 (Biomarker & Precision Oncology Forum and the 11th Asia-Pacific Gastroenterology Cancer Summit) held at Academia, Singapore, Gene Solutions showcased our trademarked MCED test, SPOT-MAS, and Minimal Residual Disease (MRD) test, K-TRACK, to oncologists from Singapore, Malaysia, India, UAE, the Philippines, and other Asian countries.

Ms. Van Anh Nguyen (MSc, Oncology Research Associate) attended the conference to present the latest data from the study “Prognostic Value of Post-Operative ctDNA in Solid Tumor Cancers.” This abstract highlighted the clinical applications of circulating tumor DNA (ctDNA) in the management of liver, colorectal, and gastric cancer, demonstrating how MRD tests like K-TRACK can help oncologists evaluate treatment responses and accurately monitor the risk of relapse.

In addition to providing MRD results, the K-TRACK test also identifies tumor profiles, including somatic mutations, germline mutations, and microsatellite instability (MSI) status. This comprehensive approach underscores the company’s commitment to “enabling access to precision oncology.”

In the field of early detection, the SPOT-MAS test garnered significant interest and inquiries from conference delegates. With the announcement that the test is now available at Gene Solutions Genomics Singapore Lab, doctors and other healthcare practitioners in the region will have a valuable tool to screen for 10 common and aggressive cancer types that currently lack effective screening methods.

Company representatives fielded questions about test accuracy, sample collection methods, laboratory certifications, and post-test management protocols. This engagement demonstrated the keen interest of oncologists in the region in understanding and applying ctDNA in multi-cancer early detection and minimal residual disease detection.

Subscribe to our latest news or follow our social media channels to receive updates on upcoming activities in Singapore.

About Gene Solutions Genomics Singapore:

The Singapore laboratory is located at Tower C, Tai Seng Exchange. This is a MOH-licensed clinical laboratory that provides genetic testing services in oncology, such as SPOT-MAS, K-TRACK, oncoGS, and oncoSure. Contact [email protected] to book a visit or discuss further how to send samples in.

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More